Abbott Laboratories (ABT) said Monday it has reached a settlement with DexCom (DXCM) to resolve all outstanding patent disputes related to continuous glucose monitoring products.
The details of the settlement remain confidential but Abbott said there are no financial payments involved in the agreement.
Abbott also said the settlement would lead to the dismissal of all pending cases in courts and patent offices worldwide. The settlement also included a provision that neither company would litigate patent, trade dress nor design rights disputes for the next 10 years.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。